Display options
Cite
Tang J, Kong D, Cui Q, et al. The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER. Onco Targets Ther. 2018;11:3551-3560doi: 10.2147/OTT.S160752.
Tang, J., Kong, D., Cui, Q., Wang, K., Zhang, D., Liao, X., Gong, Y., & Wu, G. (2018). The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER. OncoTargets and therapy, 113551-3560. https://doi.org/10.2147/OTT.S160752
Tang, Jianing, et al. "The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER." OncoTargets and therapy vol. 11 (2018): 3551-3560. doi: https://doi.org/10.2147/OTT.S160752
Tang J, Kong D, Cui Q, Wang K, Zhang D, Liao X, Gong Y, Wu G. The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER. Onco Targets Ther. 2018 Jun 19;11:3551-3560. doi: 10.2147/OTT.S160752. eCollection 2018. PMID: 29950860; PMCID: PMC6016280.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2018 Jun 19;11:3551-3560. doi: 10.2147/OTT.S160752. eCollection 2018.

The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER.

OncoTargets and therapy

Jianing Tang, Deguang Kong, Qiuxia Cui, Kun Wang, Dan Zhang, Xing Liao, Yan Gong, Gaosong Wu

Affiliations

  1. Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China.
  2. Department of General Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China.
  3. Department of Breast and Thyroid Surgery, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  4. Department of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan, China.

PMID: 29950860 PMCID: PMC6016280 DOI: 10.2147/OTT.S160752

Abstract

BACKGROUND: Papillary thyroid cancer (PTC) is a common endocrine malignancy with relatively good prognosis. Radioactive iodine (RAI) is considered effective for patients with total or nearly total thyroidectomy, but the beneficial effects of RAI are still controversial.

MATERIALS AND METHODS: To determine whether RAI therapy could improve the survival rates of PTC patients, we conducted a retrospective analysis using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. Disease-specific survival (DSS) was obtained using multivariate Cox proportional hazard regressions.

RESULTS: DSS was improved by RAI ablation in patients with tumor >2 cm, age >45 years and gross extrathyroidal or lymph node metastasis. In a further analysis, RAI therapy did not improve the DSS in patients with tumor <2 cm except those with distant metastasis. For patients with tumor >2 cm, those involving gross extrathyroidal extension, age >45 years or disease in the lymph nodes, DSS was improved after RAI therapy. Patients with distant metastasis always benefited from RAI ablation.

CONCLUSION: RAI ablation should be recommended to patients with tumor <2 cm and distant metastasis or patients with tumor >2 cm and one of the following risk factors: gross extrathyroidal extension, age >45 years, lymph node and distant metastases.

Keywords: RAI; age; extension; metastasis; prognosis; tumor size

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

  1. Cancer. 1998 Jan 15;82(2):375-88 - PubMed
  2. Endocr Relat Cancer. 2006 Dec;13(4):971-7 - PubMed
  3. Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1941-59 - PubMed
  4. Endocrine. 2012 Dec;42(3):506-13 - PubMed
  5. Cancer. 1998 Aug 1;83(3):553-9 - PubMed
  6. Surgery. 2008 Dec;144(6):1070-7; discussion 1077-8 - PubMed
  7. Cancer. 1979 Mar;43(3):810-20 - PubMed
  8. JAMA. 2017 Apr 4;317(13):1338-1348 - PubMed
  9. Am J Med. 1994 Nov;97(5):418-28 - PubMed
  10. Cancer Treat Rev. 2015 Dec;41(10):925-34 - PubMed
  11. Surgery. 2006 Dec;140(6):1043-7; discussion 1047-9 - PubMed
  12. Thyroid. 2009 Nov;19(11):1167-214 - PubMed
  13. Cancer Treat Res. 1997;89:91-140 - PubMed
  14. Eur J Endocrinol. 2006 Jun;154(6):787-803 - PubMed
  15. Surgery. 1992 Dec;112(6):1139-46; discussion 1146-7 - PubMed
  16. Thyroid. 2016 Jan;26(1):1-133 - PubMed
  17. Ann Surg Treat Res. 2014 Oct;87(4):174-9 - PubMed
  18. Clin Oncol (R Coll Radiol). 2010 Aug;22(6):419-29 - PubMed
  19. Ann Surg Oncol. 2015 Jan;22(1):158-63 - PubMed
  20. Endocr Relat Cancer. 2017 May;24(5):221-226 - PubMed
  21. Ann Surg Oncol. 2013 Feb;20(2):653-9 - PubMed
  22. Thyroid. 2006 Dec;16(12):1229-42 - PubMed
  23. Cancer. 1985 Feb 15;55(4):794-804 - PubMed
  24. Endocr Connect. 2013 Sep 23;2(3):154-60 - PubMed
  25. J Surg Oncol. 2007 Jul 1;96(1):3-7 - PubMed
  26. Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):784-95 - PubMed
  27. Ann Surg. 2011 Oct;254(4):653-60 - PubMed

Publication Types